Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Tipranavir
Drug: Ritonavir(r)
Drug: Comparator Protease Inhibitor (CPI)

First Posted Date: 2003-02-10

Last Posted Date: 2014-07-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 630

Registration Number: NCT00054717

Locations: 🇺🇸
1182.12.9 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸
1182.12.7 Boehringer Ingelheim Investigational Site, Norwalk, Connecticut, United States
🇺🇸
1182.12.1 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States

and more 114 locations

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2002-07-24

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1000

Registration Number: NCT00042068

Locations: 🇺🇸
Suite 202, Kalamazoo, Michigan, United States
🇺🇸
Suite 140, Anchorage, Alaska, United States
🇺🇸
Suite 200, Dallas, Texas, United States

and more 80 locations

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2002-05-03

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 490

Registration Number: NCT00034840

Locations: 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸
University of Conn. Health Services Center, Hypertension and Vascular Disease, Farmington, Connecticut, United States
🇺🇸
University of Maryland/Nephrology Clinical Research Unit, Baltimore, Maryland, United States

and more 32 locations

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2002-05-03

Last Posted Date: 2005-09-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 165

Registration Number: NCT00034866

Locations: 🇺🇸
University of So. California / LA County USC Medical Center, Los Angeles, California, United States
🇺🇸
Atlanta VA Medical Center, Dept. of ID, Decatur, Georgia, United States
🇺🇸
CORE Center, Cook County Hospital, Chicago, Illinois, United States

and more 46 locations

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

Phase 3

Completed

Conditions: Arthritis, Juvenile Rheumatoid

First Posted Date: 2002-05-03

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 180

Registration Number: NCT00034853

Locations: 🇺🇸
107.235.8 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸
107.235.10 Texas Scottish Rite Hospital, Dallas, Texas, United States
🇺🇸
107.235.7 Boehringer Ingelheim Investigational Site, Kansas City, Kansas, United States

and more 34 locations

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT00002166

Locations: 🇺🇸
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States

An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT00000649

Locations: 🇺🇸
Univ of Massachusetts, Worcester, Massachusetts, United States
🇺🇸
Cooper Green Hosp, Birmingham, Alabama, United States
🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2000

Registration Number: NCT00002368

Locations: 🇺🇸
Dr G Michael Wool, Los Angeles, California, United States
🇺🇸
Northwestern Univ / Division of Infectious Diseases, Chicago, Illinois, United States
🇺🇸
Rush Presbyterian / Saint Luke's Med Ctr / Infect Dis, Chicago, Illinois, United States

and more 49 locations

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT00002323

Locations: 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸
Univ TX Galveston Med Branch, Galveston, Texas, United States

and more 2 locations

The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT00002381

Locations: 🇺🇸
Saint Francis Mem Hosp / HIV Care Unit, San Francisco, California, United States
🇺🇸
Roger Williams Med Ctr, Providence, Rhode Island, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy